Survey of surgical infections currently known (SOSICK): A multicenter examination of antimicrobial use from the Surgical Infection Society Scientific Studies Committee by Mazuski, John E & al, et
Washington University School of Medicine
Digital Commons@Becker
Open Access Publications
2008
Survey of surgical infections currently known
(SOSICK): A multicenter examination of
antimicrobial use from the Surgical Infection
Society Scientific Studies Committee
John E. Mazuski
Washington University School of Medicine in St. Louis
et al
Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Mazuski, John E. and al, et, ,"Survey of surgical infections currently known (SOSICK): A multicenter examination of antimicrobial use
from the Surgical Infection Society Scientific Studies Committee." Surgical infections.9,5. 509-514. (2008).
http://digitalcommons.wustl.edu/open_access_pubs/3148
SURGICAL INFECTIONS
Volume 9, Number 5, 2008
© Mary Ann Liebert, Inc.
DOI: 10.1089/sur.2007.078
Survey of Surgical Infections Currently Known (SOSICK): 
A Multicenter Examination of Antimicrobial Use from the
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Abstract
Purpose: The Scientific Studies Committee of the Surgical Infection Society undertook the present study to ex-
amine the prevalence of and indications for antimicrobial use in intensive care units where members of the So-
ciety practice.
Methods: Information and data collection sheets were posted on the Internet for download by members inter-
ested in participating. All centers were required to obtain approval from their local human subjects research
office or equivalent. A one-week time was set during which the center could collect information on any one
day, at the center’s convenience. Data collection sheets were then sent to the lead author for analysis. Seven-
teen centers reported data for 371 patients in 22 intensive care units.
Results: Trauma and general surgical patients comprised 224 of the patients (60%). The indications for anti-in-
fective agents were prophylactic (22%), empiric (27%), therapeutic with known pathogen (41%), therapeutic
without known pathogen (e.g., cellulitis) (4%), insistence of influential practitioner (4%), or non-anti-infective
purposes (e.g., erythromycin for gastric motility) (2%). Only 44%, 29%, and 54% of the orders for prophylactic,
empiric, and therapeutic antibiotics, respectively, had date-certain stop dates. The antimicrobial drugs most
commonly used were vancomycin, piperacillin-tazobactam, and fluconazole.
Conclusion: Most patients were receiving antimicrobial agents. Polypharmacy was common. Most patients did
not have a date-certain stop date. This study sets the benchmark for future study regarding antibiotic pre-
scribing behavior in surgical intensive care units.
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THE PROFESSIONAL AND LAY PRESS abounds with reports ofoveruse and inappropriate use of antimicrobial agents.
The general public has become aware of the issues of anti-
microbial resistance and the potential for a return to the “pre-
antibiotic” era. Intensive care units (ICUs) are known for
their high antibiotic utilization and as areas of high preva-
lence of antibiotic resistance [1,2]. The Scientific Studies
Committee of the Surgical Infection Society undertook the
present study to examine the prevalence of and indications
for antimicrobial use in ICUs where members of the Surgi-
cal Infection Society practice.
Patients and Methods
A call for participation was made by an e-mail announce-
ment from the central offices of the Surgical Infection Society
to the membership. Information and data collection sheets
were posted on the Internet for download by members inter-
ested in participating (Appendix 1). All centers were required
to obtain approval from their local human subjects research
office or equivalent. A one-week time was set during which
the center could collect information on any one day, at the
center’s convenience. Data collection sheets were then sent to
the lead author for analysis. Seventeen centers reported data
for 371 patients in 22 intensive care units. Descriptive statis-
tics are presented.
Results
Table 1 shows the types of ICUs reporting, with the num-
ber of patients from each type. Table 2 shows the types of
patients enrolled. Trauma and general surgical patients com-
prised 224 of the 371 patients (60%). Eleven other specialties
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3Department of Surgery, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, New Jersey.
accounted for the remaining 40%, none of which was  10%
of the entire patient population. Forty-five patients (12%)
were hospitalized for cancer; 34 of them were receiving at
least one anti-infective agent. Twenty-eight (8%) were receiv-
ing transplant immune suppression; all 28 were receiving at
least one anti-infective agent. Figure 1 shows the distribu-
tion of the number of anti-infective agents per patient. 
Seventy-two percent were on at least one anti-infective drug.
Anti-infective agents and the number of patients receiv-
ing them are seen in Table 3. The indications for the agents
were prophylactic (22%), empiric (27%), therapeutic with
known pathogen (41%), therapeutic without known patho-
gen (e.g., cellulitis) (4%), insistence of influential practitioner
(4%), or non-anti-infective purposes (e.g., erythromycin for
gastric motility) (2%). Antibiotics ordered without a clear in-
dication, but at the insistence of an influential practitioner,
consisted of 13 drugs. Three of these (imipenem-cilastatin,
metronidazole, and piperacillin-tazobactam) made up nine
of the 20 (45%) orders for anti-infective agents at the behest
of an influential practitioner.
The indications for the antimicrobials most commonly or-
dered are shown in Table 4. The percentage of antibiotic or-
ders with a certain stop date, stratified by indication, is seen
in Figure 2. Non-anti-infective use of anti-infective drugs was
uncommon, being limited to five patients receiving erythro-
mycin for gastric motility, all from one center. No patients
were receiving fluconazole to increase serum tacrolimus con-
centrations.
Organisms causing infection can be seen in Figure 3 as a
percentage of all organisms. Specific organisms are listed in
Table 5.
Discussion
Antibiotic use has come under scrutiny in recent years as
part of the measure of the quality of surgical and medical
care [3–5]. Professional societies promulgate guidelines for
optimal use of antimicrobial drugs, our Surgical Infection So-
ciety included [6–14]. There are no standard guidelines for
the use of antimicrobials in the ICU setting, but there are
principles, some mutually contradictory, that are commonly
accepted. There are no Class 1 data to direct how antimi-
crobials should be used in the ICU. Differing schools of
thought recommend early broad-spectrum empiric antibiot-
ics vs. withholding of antibiotics until infection is proved;
restraint in the use of vancomycin vs. liberal use of vanco-
mycin in areas where the prevalence of methicillin-resistant
Staphylococcus aureus (MRSA) is high; early empiric antifun-
gal use when risk factors are present vs. withholding of an-
tifungal use until fungal infection is proved, and so on, with
various degrees of less-than-Class 1 data in support of the
recommended practices. The fact is, we do not know how
best to use antibiotics in the ICU. It seemed that a survey of
how much, what, and why would be a reasonable place to
start to gain a better understanding of what the agenda ought
to be in the design of future trials of antimicrobial use in the
ICU.
The snapshot study was designed to capture a “day in the
life” in the ICUs of members of the Surgical Infection Soci-
ety. The members of the study group reporting the data did
not necessarily direct all, or even any, of the antimicrobial
use. We did not collect data regarding who was responsible
for the management of antibiotic use, except for the one ques-
tion that asked if the indication for an antibiotic was the de-
sire of an influential practitioner, as opposed to a rational
medical indication. Four percent of antimicrobial use on the
study day was attributable to the insistence of an influential
practitioner, without a clear medical indication. Although
this number seems low, it probably would not seem so to a
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TABLE 1. TYPES OF ICUS REPORTING, WITH NUMBER OF PATIENTS FROM EACH TYPE
Number Number Number receiving
Type of ICU of units of patients anti-infective agents
Burn 2 6 4
Cardiac 1 13 6
Med/surg 6 43 32
Neuro 1 10 4
Neurotrauma 1 10 10
Surgical 11 195 139
Trauma 8 92 69
Not specified 1 2 2
Total 31 371 266
Med/surg  medical surgical; neuro  neurosurgical.
TABLE 2. TYPES OF PATIENTS ENROLLED, WITH NUMBER
RECEIVING ANTI-INFECTIVE AGENTS
Number receiving
Type of patient Number anti-infective agents
Burn 9 5
Cardiac/thoracic 32 18
ENT 5 5
General surgical 91 69
Urology 3 3
Gynecology-oncology 1 1
Medical 15 10
Neuro 25 14
Ortho 6 4
Spine 2 2
Transplant 29 28
Trauma 133 96
Vascular 13 6
Not specified 7 5
Total 371 266
ENT  ear, nose, and throat; neuro  neurosurgery; ortho 
orthopedic surgery.
quality-seeking public. Four percent is too much: We need
to approach zero.
Two hundred fifty-three of the 391 patients (65%) were re-
ceiving antimicrobial drugs on the study day. Thirty-six per-
cent of these drugs were being given for therapeutic reasons,
with a known organism. This use of anti-infective agents
probably is justified. By contrast, 32% of the antibiotics were
given empirically; it is hard to know if this use is justified.
There is intellectual disagreement among the members of the
SOSICK Study Group regarding the appropriate indications
for empiric antibiotics, and guidelines are needed.
Twenty-three percent of the antibiotics given were for pro-
phylaxis. This number is worrisome. The only indication for
which we have data that prophylaxis is effective is in the pe-
rioperative surgical situation. These data support a single dose
of prophylactic antibiotic prior to operation, and the Surgical
Care Improvement Project (SCIP) guidelines allow for as long
as 24 to 48 h of postoperative prophylaxis in some cases. If one
in five of the patients in the ICUs studied had been in the im-
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TABLE 3. ANTI-INFECTIVE DRUGS AND NUMBER OF PATIENTS RECEIVING EACH
No. 
Drug of patients
Vancomycin 69
Piperacillin-tazobactam 63
Fluconazole 42
Cefazolin 28
Linezolid 25
Metronidazole 24
Ciprofloxacin 22
Imipenem-cilastatin 20
Cefepime 16
Trimethoprim-sulfamethoxazole, levofloxacin, ganciclovir, 10–15
caspofungin, clindamycin, gentamicin, ceftriaxone
Ampicillin-sulbactam, erythromycin, tobramycin, valganciclovir, 5–9
amphotericin B lipid complex, clotrimazole, colistin, meropenem
Ampicillin, ertapenem, moxifloxacin, piperacillin, aztreonam, 5
cefoxitin, tigecycline, cloxacillin, oxacillin, rifampin, acyclovir,
amoxicillin, anidulafungin, azithromycin, cefotaxime, ceftazidime,
dapsone, daptomycin, doxycycline, itraconazole, micafungin,
minocycline, nystatin, penicillin G, sulbactam, ticarcillin-clavulanic
acid, voriconazole
TABLE 4. INDICATIONS FOR ANTIMICROBIALS USED MOST COMMONLY
No. Prophylactic Empiric Therapeutic
Drug of orders use use use
Vancomycin 69 4 33 29
Piperacillin-tazobactam 63 2 30 28
Fluconazole 42 16 8 16
Cefazolin 28 22 3 3
Linezolid 25 0 6 18
Metronidazole 24 1 11 8
Ciprofloxacin 22 3 10 8
Imipenem or meropenem 25 10 13 8
Cefepime 16 0 6 9
Number of orders is less than the sum of columns because of antimicrobial use for indications other
than prophylctic, empiric, or therapeutic.
FIG. 1. Distribution of number of anti-infective agents per
patient; 71% received at least one.
mediate perioperative period, then having 23% receiving pro-
phylactic antibiotics would be reasonable. However, a large
percentage of the orders for prophylactic antibiotics did not
have a date-certain stop date, suggesting this use was not peri-
operative. Further study is needed to understand the use of
antibiotics for prophylactic reasons in the ICU.
The subgroups of cancer and transplant patients were an-
alyzed separately because they may reasonably be expected
to have a pattern of antimicrobial utilization different from
that in the general population. It turned out this was not true
for cancer patients, but was true of transplant patients. All
transplant patients were receiving at least one antimicrobial
agent. Antimicrobial use in transplant patients is a field in
desperate need of more research.
What antimicrobials are we using? The single most-com-
monly used antimicrobial was vancomycin, a 50-year-old
drug long off patent that requires monitoring of the serum
concentration. This is consistent with the fact that most of
the infections being treated were caused by gram-positive
cocci (GPC). Another agent active only against GPC (line-
zolid) was the fifth most commonly used agent. Daptomycin
was used in only one patient (data shown as part of the 0–5
group), and quinupristin-dalfopristin was not in use in any
of the study centers on the snapshot day. The respective roles
of the various focused anti-gram-positive agents have yet to
be defined clearly.
Piperacillin-tazobactam was the second most-commonly
used agent. This is logical in light of the fact that the sec-
ond and third most common groups of organisms isolated
were gram-negative bacilli as a group and Pseudomonas. Al-
though this finding may be interpreted as overuse of a
broad-spectrum agent, it may also be seen as good antibi-
otic stewardship in that it reflects restraint in the use of car-
bapenems.
Fluconazole was the third most-commonly used agent, re-
flecting the changing ecology of ICU infection. The use of
amphotericin preparations, echinocandins, and other azole
drugs was remarkably low in comparison to the stalwart flu-
conazole. It is notable that in the ICUs surveyed, of the 16
antibiotics used at least 10 times, 10 are off-patent, generi-
cally available drugs. The scrutiny of the effects of market-
ing on physician prescribing behavior appears to be mis-
guided when applied to surgical critical care populations.
There are substantial limitations to a survey study. Data
were self-reported, and therefore subject to bias or misin-
terpretation of the definitions. We also do not have data
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TABLE 5. ORGANISMS CAUSING INFECTION
Organism No.
Staphylococcus spp. 41
Candida spp.a 20
Pseudomonas spp. 14
E. coli 13
Enterococcus spp. 13
Enterobacter spp. 11
Klebsiella spp. 9
Actinobacter spp. 9
Clostridium difficile 5
Proteus spp. 4
Haemophilus spp. 4
GNB NOSb 4
Stenotrophomonas maltophilia 4
Serratia spp. 3
Streptococcus spp. 3
Corynebacterium spp. 2
Moraxella spp. 1
Lactobacillus 1
Histoplasma 1
Burkholderia cepacia 1
Bacillus fragilis 1
Bacillus thiuringienesis 1
Citrobacter 1
aTen C. albicans, four Candida not otherwise specified, two C.
glabrata, two “yeast,” one “fungus,” one C. parapsilosis.
bGram-negative bacillus, not otherwise specified.
FIG. 2. Percentage of antibiotic orders with certain stop
date, stratified by indication. (Proph  prophylactic; Emp 
empiric; Ther  therapeutic.)
FIG. 3. Organisms causing infection, as percentage of all
organisms. (Cdiff  Clostridium difficile; GNR  gram-nega-
tive bacilli; GPC  gram-positive cocci.)
on the specific diagnoses, the resistance patterns at each
institution, or the formulary pressures placed on practi-
tioners at each center. Despite these limitations, we believe
this survey provides a baseline understanding of how we
are using antibiotics, and can be used for hypothesis gen-
eration.
In summary, we have found that (1) most patients in the
surveyed ICUs were receiving antimicrobial agents on the
snapshot day, with patients receiving more than one anti-
microbial outnumbering those on only one; (2) vancomycin,
piperacillin-tazobactam, and fluconazole were the agents
most commonly used, reflecting the ecology of the organ-
isms infecting our patients; (3) gram-negative bacilli, when
Pseudomonas spp. are included, and GPC, are most common
and similar in frequency; (4) fungi account for a substantial
portion of our infections; (5) prophylactic and empiric use of
antimicrobials is high, and further study is needed to deter-
mine if this use is appropriate; and (6) stop dates are not
present in a large number of cases. This study sets a bench-
mark for future investigation regarding antibiotic prescrib-
ing behavior in surgical ICUs.
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APPENDIX 1. DATA COLLECTION SHEET
1. What type of ICU is this patient in?
2. Type of patient:
3. Is this patient hospitalized for a diagnosis of cancer (Y/N)?
4. Is this patient on immunosuppressant medication for transplantation (Y/N)?
5. Are any systemic (not topical) antibiotics/antifungas/antivirals ordered for today (Y/N)?
6. List anti-infective drugs and organisms below, and choose an indication from the following for each bug/drug
combination.
a. Prophylactic (strictly trying to prevent an infection)
b. Empiric (high suspicion of infection, may have clinical signs, or Gram stain, or preliminary broad result, e.g.,
“GNR”)
c. Therapeutic (known pathogen)
d. Therapeutic (known infection but pathogen not identifiable, as in cellulitis)
e. Fits none of the above, but influentia practitioner insists, with free text collection of the argument for anti-
infectives (“irrational” is an acceptable answer).
f. Fluconazole to raise tacrolimus levels, or erythromycin for gastric motility, or similar non anti-infective use of
anti-infective drug.
7. Is there a date certain stop date for this anti-infective? Answer Y/N in DtCert column.
a. General surgical, not listed below b. Trauma
c. Burn d. Transplant
e. Neuro f. Cardiac/thoracic
g. Vascular h. ENT
i. Medical j. Other, please explain
a. Surgical b. Med/Surg
c. Transplant d. Trauma
e. Burn f. Cardiac
g. Neuro h. Other, please explain
Drug Indication Organism (if indication is C) DtCert (Y/N)
